120 related articles for article (PubMed ID: 31277890)
1. A capture-recapture method for estimating the incidence of off-label prescriptions: the example of baclofen for alcohol use disorder in France.
Auffret M; Rolland B; Béhal H; Labreuche J; Jouanjus E; Bordet R; Gautier S
Therapie; 2019 Dec; 74(6):645-650. PubMed ID: 31277890
[TBL] [Abstract][Full Text] [Related]
2. Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France.
Auffret M; Labreuche J; Duhamel A; Deheul S; Cottencin O; Bordet R; Gautier S; Rolland B
Drug Saf; 2017 Mar; 40(3):257-262. PubMed ID: 27988884
[TBL] [Abstract][Full Text] [Related]
3. [Involvement of pharmacists in systems for supervising off-label medications: example of the CAMTEA system for the prescription of baclofen in alcohol use disorder in Northern France].
Auffret M; Rolland B; Deheul S; Lecomte L; Cottencin O; Bordet R; Gautier S;
Ann Pharm Fr; 2014 Jan; 72(1):28-32. PubMed ID: 24438666
[TBL] [Abstract][Full Text] [Related]
4. Attitudes of community pharmacists to off-label prescribing of baclofen in Northern France.
Auffret M; Rolland B; Caous AS; Deheul S; Béné J; Cottencin O; Bordet R; Gautier S
Int J Clin Pharm; 2015 Apr; 37(2):296-9. PubMed ID: 25666941
[TBL] [Abstract][Full Text] [Related]
5. Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey.
Rolland B; Paille F; Fleury B; Cottencin O; Benyamina A; Aubin HJ
PLoS One; 2014; 9(6):e98062. PubMed ID: 24887094
[TBL] [Abstract][Full Text] [Related]
6. On-the-ground application of the 'temporary recommendation for use' regulatory measure on off-label use of baclofen for alcohol dependence in France: a regional survey of community pharmacies.
Auffret M; Rolland B; Caous AS; Gaboriau L; Deheul S; Bordet R; Gautier S
Fundam Clin Pharmacol; 2018 Apr; 32(2):234-238. PubMed ID: 29143356
[TBL] [Abstract][Full Text] [Related]
7. Comment on: "Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France".
Braillon A
Drug Saf; 2017 Apr; 40(4):359-360. PubMed ID: 28185069
[No Abstract] [Full Text] [Related]
8. Authors' Reply to Alain Braillon's Comment on "Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in France''.
Auffret M; Labreuche J; Duhamel A; Deheul S; Cottencin O; Bordet R; Gautier S; Rolland B
Drug Saf; 2017 Apr; 40(4):361-362. PubMed ID: 28188600
[No Abstract] [Full Text] [Related]
9. National diabetes programs. Application of capture-recapture to count diabetes?
Bruno G; LaPorte RE; Merletti F; Biggeri A; McCarty D; Pagano G
Diabetes Care; 1994 Jun; 17(6):548-56. PubMed ID: 8082523
[TBL] [Abstract][Full Text] [Related]
10. Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment.
Rolland B; Auffret M; Franchitto N
Expert Opin Drug Saf; 2016 Jun; 15(6):747-51. PubMed ID: 26987987
[TBL] [Abstract][Full Text] [Related]
11. [Temporary recommendation for use on off-label baclofen: viewpoint of Prescribers of the CAMTEA system].
Rolland B; Deheul S; Danel T; Bence C; Blanquart MC; Bonord A; Semal R; Briand T; Sochala M; Dubocage C; Dupriez F; Duquesne D; Gibour B; Loosfeld X; Henebelle D; Henon M; Vernalde E; Matton C; Bacquet JE; Molmy L; Sarasy F; Simioni N; Richez C; Gentil-Spinosi L; Vosgien V; Yguel J; Ledent T; Auffret M; Wilquin M; Ziolkowski D; Sochala M; Gautier S; Bordet R; Cottencin O;
Therapie; 2015; 70(2):235-8. PubMed ID: 25487850
[TBL] [Abstract][Full Text] [Related]
12. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
Chaignot C; Zureik M; Rey G; Dray-Spira R; Coste J; Weill A
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1239-1248. PubMed ID: 30251424
[TBL] [Abstract][Full Text] [Related]
13. Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol.
Rolland B; Auffret M; Labreuche J; Lapeyre-Mestre M; Dib M; Kemkem A; Grit I; Drelon M; Duhamel A; Cabe N; Vabret F; Guillin O; Baguet A; Masquelier C; Dervaux A; Deheul S; Bordet R; Carton L; Cottencin O; Jardri R; Gautier S
Expert Opin Drug Saf; 2017 Feb; 16(2):125-132. PubMed ID: 27984918
[TBL] [Abstract][Full Text] [Related]
14. [A system of prescriptions without drug approval: example of baclofen].
Rolland B; Deheul S; Danel T; Bordet R; Cottencin O
Therapie; 2010; 65(6):511-8. PubMed ID: 21176757
[TBL] [Abstract][Full Text] [Related]
15. [Baclofen and liver cirrhosis: literature review and safety precautions implemented within the system CAMTEA].
Rolland B; Deheul S; Louvet A; Gautier S; Cottencin O; Bordet R;
Therapie; 2014; 69(2):143-7. PubMed ID: 24926632
[TBL] [Abstract][Full Text] [Related]
16. [Use in France of Baclofen for Alcohol Dependence from 2007 to 2013: Cohort Study Based on the Databases SNIIRAM and PMSI].
Chaignot C; Weill A; Ricordeau P; Alla F
Therapie; 2015; 70(5):443-53. PubMed ID: 26423143
[TBL] [Abstract][Full Text] [Related]
17. Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database.
Quillet A; Colin O; Bourgeois N; Favrelière S; Ferru A; Boinot L; Lafay-Chebassier C; Perault-Pochat MC
Fundam Clin Pharmacol; 2018 Apr; 32(2):227-233. PubMed ID: 29143369
[TBL] [Abstract][Full Text] [Related]
18. Automatic detection of adverse events to predict drug label changes using text and data mining techniques.
Gurulingappa H; Toldo L; Rajput AM; Kors JA; Taweel A; Tayrouz Y
Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1189-94. PubMed ID: 23935003
[TBL] [Abstract][Full Text] [Related]
19. Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital.
Lugardon S; Desboeuf K; Fernet P; Montastruc JL; Lapeyre-Mestre M
Br J Clin Pharmacol; 2006 Aug; 62(2):225-31. PubMed ID: 16842398
[TBL] [Abstract][Full Text] [Related]
20. [Use of the capture-recapture method to assess the frequency of "serious" adverse drug reactions: experience of Toulouse University Hospital].
Montastruc JL; Lugardon S; Desboeuf K; Fernet P; Lapeyre-Mestre M
Bull Acad Natl Med; 2008 Feb; 192(2):421-30; discussion 430-1. PubMed ID: 18819693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
